Vitiligo

Researchers are testing a cream called delgocitinib on facial vitiligo, a condition where skin loses its color in patches. Twelve adults with non-segmental vitiligo on the face will apply the cream twice daily for 24 weeks. The trial measures changes in the size and severity of w…

This early-stage trial tests a new drug called TEV-53408 in 38 adults with vitiligo. The main goal is to see if the drug is safe when given as a shot under the skin. Researchers will also look for early signs that it might help bring back skin color. The study lasts 84 weeks, inc…

This study tests a daily pill called ritlecitinib in adults and teens with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color regained in a previous study, or if stopping it leads to colo…

This phase 3 trial tests an oral drug called povorcitinib in about 467 adults with nonsegmental vitiligo, a condition causing white patches on the skin. Participants take the drug or a placebo daily for 52 weeks to see if it safely improves skin color on the face and body. The go…

This study tests whether a topical cream containing ruxolitinib can safely restore skin color in people who develop white patches (vitiligo-like depigmentation) as a side effect of cancer immunotherapy. The cream is applied twice daily for 52 weeks. Researchers will measure how m…

This early-stage study tests a new medicine called DR-01 in 81 adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. Participants are randomly assigned to…

This Phase 3 study tests ritlecitinib, an oral drug, in adults with nonsegmental vitiligo, a condition causing white patches on the skin. About 1,571 participants will receive either 50 mg, 100 mg of ritlecitinib, or a placebo daily for up to 104 weeks. The goal is to see if the …

This study tests whether adding a 6-month course of methotrexate improves the results of a skin cell transplant (NCES) for adults with stable, treatment-resistant vitiligo on elbows and knees. Twenty participants will be split into two groups: one gets methotrexate before and aft…

This Phase 3 trial tests upadacitinib (Rinvoq), an oral immune-calming drug, in about 540 adults and teens with non-segmental vitiligo. Participants take a pill once daily for up to 160 weeks, with some receiving placebo first. The study measures how much skin color returns and t…

This phase 2 trial tests deucravacitinib, a daily pill that targets the immune system, to see if it can stop vitiligo from spreading and help skin regain its color. About 128 adults with non-segmental vitiligo will take the drug or a placebo for 24 weeks, then some will also rece…

This study tests whether injecting carbon dioxide gas (carboxytherapy) alongside standard narrowband UVB light therapy can improve repigmentation in people with stable vitiligo. Fifty-nine participants with symmetrical patches will receive whole-body UVB light, with carboxytherap…

This study tests whether adding a tacrolimus or tyrosine cream to standard UVB light therapy helps restore skin color in adults with vitiligo. About 67 participants will receive both creams on different patches and be followed for 3 months. The goal is to see which combination le…

This study tests a daily pill called povorcitinib to see if it can safely bring back skin color in people with nonsegmental vitiligo, a condition where white patches appear on the skin. About 450 adults will receive either the drug or a placebo for 52 weeks. The main goal is to m…

This phase 2 trial tests a gel called SHR0302Base in 155 adults with stable nonsegmental vitiligo. The goal is to see if it can improve skin color on the face and neck by at least 50%. Participants are randomly assigned to get the real gel or a placebo, and neither they nor their…

This study tests whether a cream containing rapamycin, applied daily for six months, can help restore skin color in people with vitiligo. Twenty participants aged 13 and older with nonsegmental vitiligo will apply the cream to one patch of skin and a placebo to another. The goal …

This study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …

This study looks at how a specific gene (TRPM2) might be linked to inflammation in people with vitiligo, a skin condition that causes white patches. Researchers will compare blood samples from 60 adults with vitiligo and healthy volunteers to see if certain gene variations affect…